KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Receivables (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Change in Receivables for 18 consecutive years, with -$1.2 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Receivables rose 99.82% year-over-year to -$1.2 million; the TTM value through Mar 2026 reached $158.5 million, down 53.79%, while the annual FY2025 figure was -$498.1 million, 189.91% down from the prior year.
  • Change in Receivables hit -$1.2 million in Q1 2026 for Regeneron Pharmaceuticals, down from $51.2 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $494.1 million in Q2 2024 and bottomed at -$1.2 billion in Q1 2022.
  • Average Change in Receivables over 5 years is -$18.5 million, with a median of $51.2 million recorded in 2025.
  • Year-over-year, Change in Receivables tumbled 2154.03% in 2022 and then surged 18200.0% in 2024.
  • Regeneron Pharmaceuticals' Change in Receivables stood at -$219.6 million in 2022, then skyrocketed by 137.66% to $82.7 million in 2023, then surged by 42.44% to $117.8 million in 2024, then plummeted by 56.54% to $51.2 million in 2025, then crashed by 102.34% to -$1.2 million in 2026.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$1.2 million, $51.2 million, and $80.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.